Tag: anti-neoplastic agents industry analysis

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Anti-Neoplastic Agents Market Covering 2025–2034?

The anti-neoplastic agents market has demonstrated significant growth in recent years. It is projected to expand from $130.01 billion in 2024 to $140.9 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be attributed to increasing cancer incidence, a growing demand for therapies, a rising preference for minimally invasive cancer treatments, and the need for affordable anti-neoplastic treatments.

The market for anti-neoplastic agents is projected to experience substantial expansion over the upcoming years. By 2029, this market is anticipated to reach $197.68 billion, advancing at a compound annual growth rate (CAGR) of 8.8%. This expansion during the projection period stems from factors such as enhanced patient education and awareness, government initiatives, an increasing need for individualized cancer therapies, and a heightened emphasis on improving the quality of life for cancer patients. Key developments anticipated during this timeframe involve progress in oncology research, the creation of targeted therapeutic approaches, breakthroughs in biotechnology, and improvements in diagnostic tools.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Which Major Market Drivers Are Shaping The Future Of The Anti-Neoplastic Agents Market?

The expanding prevalence of cancer cases is set to propel the growth of the antineoplastic agent market moving forward. Cancer is defined as a group of diseases where abnormal cells multiply without control in almost any organ or tissue, extending beyond their normal boundaries and potentially invading adjacent body parts or spreading to other organs. Antineoplastic agents are vital in cancer therapy, working to impede cancer cell growth and division via various methods, including causing DNA (Deoxyribonucleic acid) damage, disrupting the cell cycle, and interfering with essential cellular pathways. For example, in February 2024, recent estimates from the International Agency for Research on Cancer (IARC), a France-based international agency fostering global collaboration in cancer research, project that the global cancer burden will increase to over 35 million by 2050, marking a 77% surge from the estimated 20 million in 2022. This increasing count of cancer cases is thus a primary driver for the expansion of the antineoplastic agent market.

What Are The Major Segment Categories Driving The Anti-Neoplastic Agents Market Growth?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Which Key Trends Are Expected To Influence The Anti-Neoplastic Agents Market In The Coming Years?

Leading companies in the anti-neoplastic agent market are concentrating on developing clinical practices to maintain their standing. For instance, in March 2022, Novartis AG, a pharmaceutical corporation based in Switzerland, announced that the Food and Drug Administration’s (FDA) had approved Pluvicto. This therapy is the first targeted radioligand treatment for progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). It is advised to administer 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks, for a maximum of six doses, or until disease progression or intolerable toxicity, whichever occurs first. Patients with previously treated mCRPC should be selected for Pluvicto treatment based on PSMA expression in their tumors, utilizing Locametz or another authorized PSMA-11 imaging agent.

Who Are The Major Companies Operating In The Anti-Neoplastic Agents Market?

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

How Does The Anti-Neoplastic Agents Market Perform Across Key Geographic Regions?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Anti-Neoplastic Agents Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

Browse Through More Reports Similar to the Global Anti-Neoplastic Agents Market 2025, By The Business Research Company

Tissue Microarray Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tissue-microarray-global-market-report

Soft Tissue Sarcoma Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report

Tissue Engineering Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tissue-engineering-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Anti-Neoplastic Agents Market Size Shifted, And What Is the Outlook Through 2034?

The market for anti-neoplastic agents has been witnessing robust growth in recent years. It is projected to expand from $130.01 billion in 2024 to $140.9 billion in 2025, marking a compound annual growth rate (CAGR) of 8.4%. Factors contributing to the growth trend in the past have been a rise in the prevalence of cancer, increasing demand for treatments, escalating preference for minimally invasive procedures in cancer therapy, and the necessity for cost-effective anti-neoplastic treatment options.

The market for anti-neoplastic agents is projected to experience robust growth over the coming years, with an expected valuation of $197.68 billion by 2029, fueled by a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this projected expansion during the predicted period include increased patient education and awareness, government initiatives, a rising demand for individualized cancer therapies, and a heightened emphasis on the quality of life during cancer treatment. Key trends to watch for during the forecast period encompass progress in oncology research, the creation of targeted therapies, innovations in biotechnology, and advancements in diagnostic tools.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

What are the Fundamental Drivers and Innovations Shaping the Anti-Neoplastic Agents Market?

The rising incidence of cancer is likely to fuel the expansion of the antineoplastic agent market. Essentially, cancer is a collection of diseases with the potential to occur in virtually any organ or tissue when rogue cells proliferate uncontrollably, exceed their usual boundaries, and either metastasize to other organs or infiltrate adjacent body parts. Antineoplastic agents are vital in combating cancer, limiting the growth and division of cancerous cells through multiple strategies, such as causing DNA damage, hindering the cell cycle, and disrupting crucial cellular pathways. For example, the International Agency for Research on Cancer (IARC), based in France and dedicated to fostering international cooperation in cancer research, reported in February 2024 that the cancer burden is anticipated to rise to over 35 million by 2050, marking a 77% increase from the estimated 20 million in 2022. Therefore, the sharp rise in cancer diagnoses is propelling the antineoplastic agent market’s expansion.

How Is the Anti-Neoplastic Agents Market Segmented?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

Which Regions Are Driving the Next Phase of the Anti-Neoplastic Agents Market Growth?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Trends Are Shaping the Future of the Anti-Neoplastic Agents Market?

Leading firms in the anti-neoplastic agent market are striving to innovate clinical methods to maintain their market standing. For instance, Novartis AG, a pharmaceutical corporation based in Switzerland, declared in March 2022 that it received the Food and Drug Administration’s (FDA) approval for Pluvicto, which is the first-ever targeted radioligand treatment for progressive, PSMA positive metastatic castration-resistant prostate cancer (mCRPC). It is advised to administer 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks, up to a maximum of six doses, or until the disease progression becomes unbearable or toxicity levels peak. The selection of patients with previously treated mCRPC for treatment with Pluvicto should be based on the expression of PSMA in tumors, using Locametz or another authorized PSMA-11 imaging agent.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

How Is the Anti-Neoplastic Agents Market Defined and What Are Its Core Parameters?

Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Anti-Neoplastic Agents Market Growth in 2025?

In recent times, the market size for anti-neoplastic agents has experienced substantial growth. The market value, which is set to rise from $130.01 billion in 2024 to $142.82 billion in 2025, will do so at a compound annual growth rate (CAGR) of 9.9%. The expansion during the historic period can be linked to factors such as a rise in cancer cases, a growing need for therapies, an increased preference for minimally invasive cancer treatments, and the demand for cost-effective anti-neoplastic treatments.

What Is the Forecast for the Anti-Neoplastic Agents Market Size Through 2029?

The market size for anti-neoplastic agents is poised for robust expansion in the coming years, with a projection to reach $202.12 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth over the forecast timeframe can be attributed to factors such as the increasing knowledge and awareness among patients, government initiatives, the rising trend of individualized cancer treatments, and an enhanced emphasis on quality of life during cancer treatment. Key trends expected during the forecast period are progress in oncology research, the evolution of targeted therapies, innovations in biotechnology, and advances in diagnostic tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

What are the Key Market Players in Anti-Neoplastic Agents Market and How They’re Evolving?

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

What Are the Primary Growth Drivers in the Anti-Neoplastic Agents Market?

The growth of the antineoplastic agent market is predicted to be spurred by the escalating number of cancer cases. Cancer, a group of diseases that can occur in virtually any organ or tissue in the human body, arises when irregular cells multiply out of control, exceed their usual limits and either spread to other organs or infiltrate nearby body parts. Antineoplastic agents are crucial to cancer treatment as they stall the growth and division of cancer cells using several mechanisms such as DNA damage, cell cycle interruption, and disruption of vital cellular pathways. For instance, in February 2024, the International Agency for Research on Cancer (IARC), a French-based global agency that encourages international cooperation in cancer research, reported the latest global cancer burden estimates. According to these, the cancer burden is projected to increase to over 35 million in 2050, reflecting a jump of 77% compared to an estimated 20 million in 2022. As a result, the rising frequency of cancer cases is fueling the expansion of the antineoplastic agent market. The anti-neoplastic agent market’s growth is also expected to be spurred by an increase in investment in cancer research. Such investment involves supplying financial resources to aid scientific initiatives focused on studying, preventing, diagnosing, and treating cancer. Enhanced funding for cancer research enables pharmaceutical and biotech companies to push forward in discovering, developing, and thoroughly testing new anti-neoplastic agents. This includes identifying drug targets and creating potential candidates. For instance, the Department of Health and Aged Care, an Australian government entity, invested $893.5 million in March 2022 to augment cancer services and outcomes. This figure incorporated $329.4 million for new cancer drugs like Trodelvy for triple-negative breast cancer, Lynparza for metastatic castration-resistant prostate cancer, and Mylotarg for acute myeloid leukemia, which could benefit hundreds of patients each year. Therefore, increased investment in cancer research is likely to stimulate the growth of the anti-neoplastic agent market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

What Are the Leading Segments in the Global Anti-Neoplastic Agents Industry?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

What Are the Key Market Trends in the Anti-Neoplastic Agents Industry?

Leading firms in the anti-neoplastic agent industry are concentrated on advancing their clinical procedures to maintain market dominance. For example, in March 2022, Switzerland’s pharmaceutical firm, Novartis AG, publicized the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto, a pioneering targeted radioligand therapy, has been developed to treat progressive, Prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The treatment involves the administration of 7.4 GBq (200 mCi) of Pluvicto intravenously, every six weeks, capping at six rounds or in cases of disease progression or intolerable toxicity. Patients with mCRPC who have received prior treatment should be considered for Pluvicto therapy, depending on their tumor’s PSMA expression, assessed using Locametz or another FDA-approved PSMA-11 imaging agent.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

What Is the Regional Outlook for the Anti-Neoplastic Agents Market?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

This Report Delivers Insight On:

1. How big is the anti-neoplastic agents market, and how is it changing globally?

2. Who are the major companies in the anti-neoplastic agents market, and how are they performing?

3. What are the key opportunities and risks in the anti-neoplastic agents market right now?

4. Which products or customer segments are growing the most in the anti-neoplastic agents market?

5. What factors are helping or slowing down the growth of the anti-neoplastic agents market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the anti-neoplastic agents industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Anti-Neoplastic Agents Market In 2029?

The market size for anti-neoplastic agents has seen significant growth in recent years. This market is projected to increase from a value of $130.01 billion in 2024 to reach $142.82 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this upward trend during the historical period include a rise in cancer cases, an increased need for treatments, a growing preference for minimally invasive cancer treatments, as well as a demand for cost-effective anti-neoplastic treatments.

Expectations are high for significant growth in the anti-neoplastic agents market over the upcoming years. Forecasts suggest an increase to $202.12 billion by 2029, with an impressive compound annual growth rate (CAGR) of 9.1%. Such optimistic projections are due mainly to factors such as patient enlightenment and awareness, government-driven initiatives, an upsurge in demand for individualized cancer treatment, and an increased focus on quality of life during cancer treatment. Additionally, key trends predicted within this period involve progress in oncological research, the production of targeted therapies, biotechnological innovations, and advancements in diagnostic equipment.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Which Factors and External Forces Are Driving Demand in the Anti-Neoplastic Agents Market?

An upswing in cancer incidences is projected to bolster the antineoplastic agent market’s expansion. Cancer comprises a group of diseases that originate in almost any organ or tissue when rogue cells multiply unchecked, beyond their typical boundaries, and either spread to various parts or invade nearby areas of the body. Antineoplastic agents are crucial in treating cancer by curtailing cancer cell proliferation and division through several methods, like causing DNA (Deoxyribonucleic acid) harm, disrupting the cell cycle and meddling with critical cellular pathways. As per the February 2024 forecast by the France-based International Agency for Research on Cancer (IARC), promoting global cooperation in cancer research, the cancer burden may escalate to over 35 million by 2050, marking a 77% surge from the projected 20 million in 2022. Consequently, the rise in cancer instances is spurring the antineoplastic agent market’s growth.

Market Driver for Anti-Neoplastic Agents: Elevated Investment in Cancer Research Fuels Anti-Neoplastic Agent Market’s Growth

 

Which Segments in the Anti-Neoplastic Agents Offer the Most Growth?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

What Are the Fastest-Growing Geographies in the Anti-Neoplastic Agents Market?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Cutting-Edge Market Trends Are Expected to Drive the Anti-Neoplastic Agents Market’s Growth?

Top firms in the anti-neoplastic agent market are prioritizing the development of clinical practices to maintain their market standing. Take for example, Novartis AG, a pharmaceutical corporation based in Switzerland, who in March 2022, secured approval from the Food and Drug Administration (FDA) for Pluvicto, marking it as the first ever targeted radioligand therapy designed to treat progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). The recommendation is for 7.4 GBq (200 mCi) of Pluvicto to be given intravenously in six-week intervals, for no more than six doses, or until the disease progresses or the toxicity becomes unbearable, whichever occurs first. Patients with mCRPC who have previously undergone treatment are selected for Pluvicto therapy, relying on the PSMA expression in tumors, by utilizing Locametz or another PSMA-11 imaging agent authorized for this purpose.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

What Are the Key Elements That Define the Anti-Neoplastic Agents Market?

Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theAnti-Neoplastic Agents Market?

The antineoplastic agent market is likely to see significant growth due to the increasing prevalence of cancer. Cancer is not a single disease but rather a range of conditions that occur when cells within the body start to grow and spread uncontrollably, breaking their normal boundaries, and can spread to other organs or invade nearby tissues. These abnormal cell proliferations can occur in almost any organ or tissue. Antineoplastic agents are critical in the treatment of cancer as they inhibit the growth and division of cancer cells through a variety of methods, such as causing DNA damage, disrupting the cell cycle, and interfering with important cellular pathways. For example, according to the International Agency for Research on Cancer (IARC) – a France-based agency promoting international cancer research collaboration – the global cancer burden is predicted to rise by 77% to over 35 million in 2050 from the projected 20 million in 2022. Accordingly, the escalating cases of cancer are fuelling the expansion of the antineoplastic agent market.

Anti-Neoplastic Agents Market Driver: Increased Cancer Research Investment Drives Growth Of Anti-Neoplastic Agent Market

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

How Will the Growth Rate of theAnti-Neoplastic Agents Market Impact Industry Trends by 2034?

The market size of anti-neoplastic agents has seen significant expansion in the past few years. Its growth is projected to go from $130.01 billion in 2024 to $142.82 billion in 2025, showing a compound annual growth rate (CAGR) of 9.9%. Factors such as the rising incidences of cancer, the increasing demand for treatment schemes, the growing interest in minimally invasive cancer treatments, and the need for cost-effective anti-neoplastic treatments are driving the growth witnessed in the historical period.

The market size for anti-neoplastic agents is anticipated to experience robust growth in the coming years, with projections suggesting it will reach $202.12 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.1%. This substantial growth during the prediction period can be credited to factors such as increased patient knowledge and awareness, government initiatives, a rising demand for tailored cancer treatments, and an enhanced focus on life quality during cancer treatment. The forecast period will also see major trends such as advancements in oncology research, the growth of targeted therapies, innovations in biotechnology, and improvements in diagnostic tools.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

Which Cutting-Edge Market Trends Are Expected to Drive theAnti-Neoplastic Agents Market’s Growth?

Leading corporations in the anti-neoplastic agent market are constructing strategic clinical approaches in order to maintain their industry dominance. For example, in March 2022, Novartis AG, a pharmaceutical company with roots in Switzerland, received approval from the Food and Drug Administration (FDA) for Pluvicto, a novel targeted radioligand therapy specifically designed to treat advanced, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). The recommended dosage is 7.4 GBq (200 mCi) of Pluvicto to be administered intravenously every six weeks, with the treatment limited to either six doses in total, until disease advances, or until toxicity becomes unbearable. The selection criteria for Pluvicto treatment should be based on the level of PSMA expression in tumor cells, and previous mCRPC treatment patients should be considered using Locametz or a similar PSMA-11 imaging agent authorized for such uses.

What Are the Leading Market Players Impacting theAnti-Neoplastic Agents Market’s Growth Trend?

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

How Are the Key Segments of the Anti-Neoplastic Agents Market Driving Opportunities and Innovations?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theAnti-Neoplastic Agents Market?# Market Expansion?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Anti-Neoplastic Agents Market 2025, By The Business Research Company:

Esophagoscopes And Gastroscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/esophagoscopes-and-gastroscopes-global-market-report

Flexible Endoscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/flexible-endoscopes-global-market-report

Abdominal Aortic Aneurysm (AAA) Repair Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/abdominal-aortic-aneurysm-aaa-repair-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the anti-neoplastic agents market size evolved in recent years?

Growth in the market size of anti-neoplastic agents has been robust in the past few years. The market is projected to expand from $130.01 billion in 2024 to $142.82 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this historic period growth include higher instances of cancer, heightened need for therapies, a surge in demand for less invasive cancer treatments, and a call for cost-effective anti-neoplastic treatments.

What are the predictions for the anti-neoplastic agents market size in the coming years?

Over the following years, the anti-neoplastic agents market is anticipated to experience robust growth. The market size will escalate to $202.12 billion in 2029, with a compound annual growth rate (CAGR) of 9.1%. The growth predicted in this time frame is credited to patient education and awareness programs, government initiatives, an increasing need for individualized cancer treatments, and a heightened focus on maintaining a quality life while undergoing cancer treatments. The future trends to look out for during this period include progressive oncology research, the creation of targeted therapies, advancements in biotechnology, and innovation in diagnostic tools.

Get your anti-neoplastic agents market report here!

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

What key factors are fueling the growth of the anti-neoplastic agents market?

The escalating number of individuals diagnosed with cancer is predicted to fuel the expansion of the antineoplastic agent market. Cancer is a type of disease that can originate in virtually any organ or tissue in the body. It occurs when abnormal cells grow uncontrollably, overcome their usual boundaries, and spread to other organs or intrude on adjacent body parts. Antineoplastic agents are pivotal in cancer therapy as they halt the growth and division of cancer cells through various tactics such as DNA damage, cell cycle disturbance and interruption of crucial cellular pathways. For example, the International Agency for Research on Cancer (IARC), a France-based agency that fosters international cooperation in cancer research, projected that the cancer burden would escalate to more than 35 million by 2050, a 77% hike from the approximated 20 million in 2022. Thus, the rising number of diagnosed cancer cases is stimulating the expansion of the antineoplastic agent market. Increased investment in cancer research is expected to drive the anti-neoplastic agent market growth. Funding for cancer research involves supplying financial aid to back up scientific projects focused on studying, preventing, diagnosing and treating cancer. Enhanced funding enables pharmaceutical and biotech firms to explore the invention, development and exhaustive testing of new anti-neoplastic agents, including the identification of drug targets and synthesis of potential treatments. For example, in March 2022, the Department of Health and Aged Care, an Australian government organization, dedicated $893.5 million to improve cancer services and results. This funding includes $329.4 million for new cancer drugs such as Trodelvy for triple-negative breast cancer, Lynparza for metastatic castration-resistant prostate cancer and Mylotarg for acute myeloid leukemia, this could benefit countless patients per year. Therefore, the upward trend in cancer research funding is set to spur the growth of the anti-neoplastic agent market.

How is the global anti-neoplastic agents market divided into key segments?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Who are the key firms paving the way for growth in the anti-neoplastic agents market?

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Which trends are expected to transform the anti-neoplastic agents market?

Key players in the anti-neoplastic agent market are honing their clinical practices to solidify their market standing. An example from March 2022 would be Novartis AG, a pharmaceutical firm headquartered in Switzerland, which declared that Pluvicto, the pioneer targeted radioligand therapy for progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC), was approved by the Food and Drug Administration (FDA). Every six weeks, patients are administered with 7.4 GBq (200 mCi) of Pluvicto intravenously, up to a maximum of six doses or until the disease worsens or intolerable toxicity is experienced. Patients with mCRPC who’ve received previous treatment should be selected for Pluvicto therapy based on the level of PSMA expression in their tumors, using Locametz or another approved PSMA-11 imaging agent.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

What regions are contributing significantly to the growth of the anti-neoplastic agents market?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Esophagoscopes And Gastroscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/esophagoscopes-and-gastroscopes-global-market-report

Flexible Endoscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/flexible-endoscopes-global-market-report

Abdominal Aortic Aneurysm (AAA) Repair Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/abdominal-aortic-aneurysm-aaa-repair-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the Anti-Neoplastic Agents Market, and What Factors Will Drive It?

The market for anti-neoplastic agents has experienced significant expansion in the previous years. It is projected to increase from $130.01 billion in 2024 to $142.82 billion in 2025 with a Compound Annual Growth Rate (CAGR) of 9.9%. This exponential increase during the historical period can be attributed to factors such as a rise in cancer cases, heightened demand for therapeutic treatments, an increase in preference for minimally invasive cancer treatment, along with the need for cost-effective anti-neoplastic remedies.

The market for anti-neoplastic agents is predicted to experience robust expansion in the upcoming years, escalating to $202.12 billion in 2029 with a compound annual growth rate (CAGR) of 9.1%. The proliferation in this projected period can be linked to increased patient knowledge and awareness, governmental efforts, a rising demand for individualized cancer treatment, and a growing emphasis on quality of life during cancer care. Noteworthy trends within this forecast period encompass progress in oncology research, the creation of targeted therapies, biotechnological advancements, and improvements within diagnostic instruments.

How Are the key drivers expanding the growth of the anti-neoplastic agents Market?

The anticipated growth of the antineoplastic agent market is largely tied to the surge in cancer cases. Cancer encompasses a range of diseases that occur when abnormal cells grow out of control, breach their typical boundaries, and either invade neighboring bodily parts or spread to different organs. Antineoplastic agents are critical to cancer therapy as they curb cancer cell growth and multiplication via several methods, such as damaging DNA, disrupting the cell cycle, and interfering with essential cellular pathways. For example, the International Agency for Research on Cancer (IARC) – a French-based international body promoting global cancer research collaboration – estimates that the global cancer burden would rise to over 35 million in 2050, up by 77% from the projected 20 million in 2022 come February 2024. Hence, the mounting number of cancer cases is fueling growth in the antineoplastic agent market. Influence on the Anti-Neoplastic Agents Market: Surge in Cancer Research Investment Spurs Anti-Neoplastic Agent Market Growth

Get Your Free Sample of the Global Anti-Neoplastic Agents Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Who Are the Top Companies Contributing to the Growth of the Anti-Neoplastic Agents Market?

Major companies operating in the anti-neoplastic agents market are:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche Ltd._x000D_

• Merck & Co. Inc._x000D_

• Bayer AG_x000D_

• Novartis AG_x000D_

How Are Technological Trends Affecting the Growth and Development of the Anti-Neoplastic Agents Market?

Leading corporations within the anti-neoplastic agent market are striving to innovate in clinical practices to maintain their market position. For example, the pharmaceutical company based in Switzerland, Novartis AG, reported the approval of Pluvicto by the Food and Drug Administration (FDA) in March 2022. This is the first targeted radioligand therapy intended for the treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer (mCRPC). The recommendation is to administer 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks, with a cap of six doses, or until disease progression or intolerable toxicity, whichever occurs first. Pluvicto is to be used to treat patients with previously treated mCRPC, based on the presence of PSMA in tumors, using Locametz or other approved PSMA-11 imaging agents for selection.

Get Instant Access to the Global Anti-Neoplastic Agents Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

Which Primary Segments of the Anti-Neoplastic Agents Market Are Driving Growth and Industry Transformations?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

What Are the Key Regions Powering Growth in the Anti-Neoplastic Agents Market?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Defining Features of the Anti-Neoplastic Agents Market?

Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.

Browse Through More Similar Reports By The Business Research Company:

Esophagoscopes And Gastroscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/esophagoscopes-and-gastroscopes-global-market-report

Flexible Endoscopes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/flexible-endoscopes-global-market-report

Abdominal Aortic Aneurysm (AAA) Repair Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/abdominal-aortic-aneurysm-aaa-repair-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: